10,985 Call Contracts Traded on Sun Pharmaceutical Industries Ltd as Stock Rallies 2.3% in Two-Day Streak

Options Event and Cash Market Price Action

The most actively traded call options on Sun Pharmaceutical Industries Ltd were those with a strike price of Rs 1,900, expiring on 26 May 2026. With 10,985 contracts traded and a turnover of approximately Rs 923.9 lakhs, this activity represents a significant directional wager ahead of expiry in just over two weeks. The underlying stock price at Rs 1,876.3 is marginally below the strike, placing these calls slightly out-of-the-money (OTM). This suggests that traders are speculating on a near-term upside move beyond the current price level, rather than hedging existing positions.

The stock’s recent performance supports this view, having risen 2.31% over the last two sessions and hitting a new 52-week high of Rs 1,885.8 during intraday trading. This momentum in the cash market is consistent with the surge in call option activity — is the options market anticipating a breakout or simply reflecting recent gains?

Strike Price and Moneyness Analysis

The Rs 1,900 strike price is just Rs 23.7 above the current stock price, placing these calls in the near-the-money category. This positioning is often favoured by traders seeking leveraged exposure to a potential rally without paying the premium for deep in-the-money options. The proximity to the underlying price means these options are sensitive to small price movements, amplifying gains if the stock crosses the strike before expiry.

Given the expiry date of 26 May 2026, the time horizon is short, indicating a tactical bet on a near-term price advance rather than a long-term directional view. The choice of an OTM strike rather than an in-the-money strike suggests a speculative upside bet rather than a hedging strategy, which would typically involve deeper in-the-money options.

This strike selection reveals the nature of the bet — is this a signal of confidence in a sustained rally or a tactical play on short-term volatility?

Open Interest and Contracts Analysis

Open interest (OI) at the Rs 1,900 strike stands at 4,038 contracts, while 10,985 contracts were traded on 11 May 2026. This results in a contracts-to-OI ratio of approximately 2.7:1, a figure that points to substantial fresh positioning rather than mere rotation of existing holdings. Such a high ratio indicates that new money is flowing into these call options, reinforcing the view of a directional bet rather than profit-taking or hedging.

The elevated turnover and fresh open interest accumulation suggest that market participants are actively building exposure to potential upside in Sun Pharmaceutical Industries Ltd. This is particularly notable given the proximity to expiry, which typically sees a reduction in open interest as positions are closed or exercised.

Such dynamics raise the question: does this fresh call buying reflect a genuine directional conviction or a short-term speculative surge?

Cash Market Context: Momentum and Moving Averages

Sun Pharmaceutical Industries Ltd is trading comfortably above its key moving averages — 5-day, 20-day, 50-day, 100-day, and 200-day — signalling a robust upward trend. The stock’s ability to sustain levels above these averages supports the bullish interpretation of the call option activity.

Moreover, the stock outperformed its sector by 0.82% on the day of heavy call trading, while the broader Sensex declined by 0.93%. This relative strength in the cash market aligns with the directional positioning seen in the options market — does this alignment suggest a momentum-driven rally or a short-lived spike?

Delivery Volume and Liquidity Considerations

Despite the surge in call option activity, delivery volumes in the cash market have shown a decline. On 8 May 2026, delivery volume was 19.44 lakh shares, down 15.39% against the 5-day average. This falling investor participation in the cash segment contrasts with the rising derivatives activity, indicating that the bullish conviction is currently more pronounced in the options market than in actual shareholding.

Liquidity remains adequate, with the stock’s traded value supporting sizeable trade sizes of around Rs 12.05 crore based on 2% of the 5-day average traded value. This ensures that the options activity is supported by a liquid underlying, reducing the risk of price distortions due to illiquidity.

This divergence between delivery volumes and call activity raises an important question: is the options market leading the cash market or is there a disconnect that warrants caution?

Key Data at a Glance

Conclusion: What the Options and Cash Data Collectively Signal

The heavy call option activity at the Rs 1,900 strike price, combined with the stock’s recent gains and strong technical positioning above key moving averages, paints a picture of bullish directional positioning in Sun Pharmaceutical Industries Ltd. The contracts-to-open interest ratio indicates fresh money entering the market, while the near-term expiry adds urgency to this bet.

However, the decline in delivery volumes suggests that this optimism is currently more pronounced in the derivatives market than in actual shareholding, introducing a note of caution. The divergence between cash and derivatives markets invites the question: should traders prioritise the momentum in options or the more subdued cash market participation?

Limited Period Only. Get Started for only Rs. 16,999 - Get MojoOne for 2 Years + 1 Year Absolutely FREE! (72% Off) Get 72% Off →